- To allow for necessary ID and HIV funding in FY2020, we urge Congress to take immediate steps to negotiate a new high-level budget agreement that raises overall spending caps. We will also advocate for robust investment in specific ID and HIV programs.
- Include personal stories about the importance of global and domestic ID and HIV programs to you and your colleagues, your patients and your community.
FY2020 Overall Asks
- Support Robust Funding for ID and HIV Programs in FY2020: We urge support for FY2020 spending priorities that provide necessary resources for ID and HIV programs across the Department of Health and Human Services, State Department (which houses PEPFAR), and US Agency for International Development. Infectious diseases pose serious dangers to patient safety, public health and national security. Federally supported efforts are critical to preventing and responding to infectious diseases threats.
- Choose some of the IDSA funding requests below to highlight during your meeting. Focus on those most meaningful to your work and your community. IDSA staff will refer congressional staff to our fact sheet for the complete list of requests.
FY2020 CDC Request
- Antibiotic Resistance Solutions Initiative ($200 million): This initiative requires a funding level of $200 million to expand Healthcare-Associated Infections (HAI)/AR prevention efforts to 50 states, six large cities, and Puerto Rico. The investment would enable direct action to implement proven interventions that reduce emergence and spread of AMR pathogens and improve appropriate antibiotic use.
- Elimination of Opioid Related Infectious Diseases ($58 million): The SUPPORT Act expanded the Public Health Services Act to enhance the prevention and treatment of infectious diseases commonly associated with injection drug use and authorizes $40 million in funding to CDC to expand surveillance for infectious diseases commonly associated with injection drug use, including HIV, viral hepatitis and infective endocarditis. Given the significant and growing burden of the opioid epidemic, we strongly urge that Congress provide $40 million to address infectious diseases associated with the opioid epidemic.
- National Healthcare Safety Network ($22.75 million): CDC aims to enhance NHSN reporting to more than 20,000 healthcare facilities across the continuum of care. While progress has been made in the number of healthcare facilities voluntarily reporting antibiotic use and resistance data, more work is needed to achieve the stated goal in the National Action Plan for Combating Antibiotic Resistant Bacteria for 95% of hospitals to report these data by 2020. FY2020 funding will enable CDC to continue to provide data for national HAI elimination as well as tracking national antibiotic use and resistance data essential to inform and evaluate antibiotic stewardship activities and other efforts to address antibiotic resistance.
- Advanced Molecular Detection Initiative ($32.5 million): Funding of $32.5 million would allow CDC to more rapidly determine where emerging diseases come from, whether microbes are resistant to antibiotics, and how microbes are moving through a population. The AMD strengthens CDC’s epidemiologic and laboratory expertise to effectively guide public health action.
- CDC Global Health ($642 million): $642 million for the Center for Global Health would help protect Americans by improving global health capacity to stop threats before they reach domestic soil. Funding would support the global HIV program, which, as a key implementer of PEPFAR, facilitates access to life-saving antiretroviral treatment for millions. The Center works to find, cure and prevent TB, eliminate the global burden of malaria, stop poliovirus transmission, and reduce mortality from vaccine-preventable diseases. Public health experts address more than 400 diseases and health threats in 60 countries. The CDC is a key implementer of the Global Health Security Agenda, which will lose funding in September of 2019, if additional resources aren’t committed for current programs
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention ($1.470 billion): We urge Congress to provide robust funding of $1.470 billion so that CDC can continue to reduce new HIV infections and address the growing number of syphilis cases and increases in hepatitis and tuberculosis.
- The Immunization Grant Program ($750 million): $750 million for the CDC’s Immunization Program would allow providers to obtain and store vaccines; establish and maintain vaccine registries and educate the public about the importance of vaccines to help decrease the annual number of adult deaths from vaccine-preventable illnesses and prevent outbreaks of diseases due to low vaccination rates. Several US states, including NY, WA and TX, are experiencing measles outbreaks in 2019 linked to depressed immunization rates. This growing trend underscores the urgent need for increased investment.
FY2020 NIH Request
- National Institute of Allergy and Infectious Diseases ($5.761 billion): Congress should provide robust funding of at least $5.761 billion for NIAID in FY2020. We urge Congress to continue to grow, not shrink NIAID’s capacity to find cures for infectious diseases. Funding at this level would allow NIAID to address antibiotic resistance while carrying out its broader role in supporting infectious diseases research. This includes research on new treatments, diagnostics and vaccines for tuberculosis, HIV, emerging infections, and other infectious disease threats. NIAID would also be able to continue to develop and implement programs and initiatives designed to attract and retain physician-scientists, including the “Pathway to Independence” program for eligible physician-scientists. The program would help to increase the number of physician-scientists conducting biomedical research.
- Fogarty International Center ($83 million): Congress should provide full funding of at least $83 million for the Center in FY2020. The Fogarty Center is instrumental to our nation’s global standing, global health security and our ability to detect and respond to pandemics. U.S. patients and researchers benefit from Fogarty funded breakthroughs on diseases including HIV, tuberculosis, malaria, cancer, diabetes, and heart disease. More than 80 percent of Fogarty’s extramural grant budget goes to U.S. academic institutions and 100 percent of funding engages U.S scientists and researchers.
FY2020 Assistant Secretary for Preparedness and Response (ASPR) Request
- Biomedical Advanced Research and Development Authority ($750 million): The BARDA broad spectrum antimicrobials program leads efforts to leverage partnerships with public and private partners to develop products that directly support the government‐wide National Action Plan for Combating Antibiotic‐Resistant Bacteria. In recent years, efforts by BARDA and industry partnerships have resulted in new broad-spectrum antibiotics. The President’s Council of Advisors on Science and Technology has recommended $800 million per year to BARDA to support partnerships with industry.
FY2020 US Agency for International Development (USAID) and Department of State Request
- USAID Tuberculosis Program ($400 million) and the Global Fund to Fight AIDS, Tuberculosis and Malaria ($1.56 billion): Recommended funding for USAID’s TB program and the Global Fund will not only allow continued reductions in malaria and TB, but help staunch the growth of drug-resistant forms of these infections, particularly of drug-resistant forms of tuberculosis, which is the only airborne drug resistant disease and the biggest infectious disease killer globally.
FY2020 Bilateral Global Health Security Programs Request
- Renew funding for Global Health Security Agenda: Across multiple agencies, including CDC and USAID, $1 billion in Global Health Security Agenda funding from 2014 through 2019 has supported global AMR activities, including training health providers to prevent health-care associated infections – which often contribute to AMR – and expanding surveillance of drug-resistant bacteria. Congressional action is needed this year to extend this funding beyond 2019, or most of these vital global health security activities will cease.